Physician profile
Marc Schwartz
NPI 1700997079
$2,080.92
in general payments reported to CMS, 2019-2025
19 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $213 · 2021: $157 · 2022: $311 · 2023: $96.59 · 2024: $298 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $556.47 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $290.73 | 2019-2022 | |
| Pfizer INC. | $231.89 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.01 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $145.50 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $121.09 | 2019 | |
| Merck Sharp & Dohme LLC | $98.45 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $92.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $82.02 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $43.42 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $43.18 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $39.63 | 2019-2024 | |
| Heartflow, INC. | $23.47 | 2025 | |
| Daiichi Sankyo INC. | $22.44 | 2020 | |
| Akcea Therapeutics, INC. | $21.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.71 | 2019 | |
| Infobionic, INC | $19.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.